Teva denies rumors of CEO-board friction

Share this article:

A report from Israel's Channel 2 suggests there's some discord among Teva brass, an allegation Teva management was quick to refute.

The segment, as reported by news services Bloomberg and Reuters, suggests that CEO Jeremy Levin and chairman Phillp Frost are at odds over the company's cost-savings plans—particularly over layoffs.

The company issued a statement in response, saying: “These are baseless claims. The company's management has worked to craft and execute its strategy with complete cooperation from the board of directors. All decisions made by the company's management, led by its CEO, have been made with consultation and agreement of the board. The chairman and the CEO conduct regular work meetings and conversations, as is customary.”

Earlier this month, Teva said it would cut 10% of its workforce, or 5,000 jobs, in 2014. The company said it expects to save $2 billion a year by the end of 2017. As to whether any of the layoffs include sales or marketing, a spokesperson told MM&M the firm has "not taken any decisions yet on reductions in specific businesses."

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.